Delivered 12% full-year revenue growth despite 2025 being only the third time in 25 years that U.S. injectable volumes declined.
Attributed Jeuveau’s 14% market share capture to a ‘beauty-first’ strategy that aligns with cash-pay aesthetic practices rather than reimbursement models.
Successfully piloted a new portfolio growth rebate program designed to incentivize accounts to consolidate their toxin and filler spend with Evolus.
Expanded the Evolysse HA filler footprint to over 3,000 purchasing accounts, leveraging Cold-X Technology to meet consumer demand for natural-looking results.
Executed a structural expense reset in mid-2025 to align the organization for durable, profitable growth and meaningful operating leverage.
International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and approaching double-digit share in the U.K.
Maintained brand resilience through Evolus Rewards, an SMS-based loyalty program that has grown to over 1.4 million treated patients.
Projecting 2026 total net revenue between $327 million and $337 million, assuming a low single-digit toxin market recovery and a low single-digit filler market decline.
Anticipating full-year 2026 profitability with low to mid-single-digit adjusted EBITDA margins, supported by a largely flat non-GAAP operating expense base.
Planning the European launch of Estyme in the second quarter of 2026 and expecting FDA approval of Evolysse Sculpt in the fourth quarter.
Initiating a large-scale sampling and experience program for Evolysse in Q2 2026 to broaden adoption ahead of the Sculpt flagship launch.
Reiterating 2028 targets of $450 million to $500 million in revenue with 13% to 15% adjusted EBITDA margins as the portfolio scales.
Implemented a new revolving credit facility providing up to $40 million in liquidity to fund working capital and inventory for upcoming product launches.
Confirmed that Jeuveau is currently unaffected by tariffs, while Evolysse is subject to a 15% tariff assumption in the 2026 guidance.
Transitioned the primary profitability metric to adjusted EBITDA starting in 2026 to improve comparability with industry peers.
Stated a clear intention to avoid raising equity capital, focusing instead on existing cash reserves and debt tranches to maintain shareholder value.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
finance.yahoo.com
#Evolus #Earnings #Call #Summary
